- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Topical gel shows promising Results for Treatment of Skin Toxicities due to cancer treatment in Phase 2a trial
A novel topical gel, HT-001, shows promise as a treatment for cutaneous side effects caused by epidermal growth factor receptor inhibitor (EGFRi) cancer therapy. According to a press release from Hoth Therapeutics detailing phase 2a interim data, these results mark a significant milestone for addressing an unmet need in cancer treatment. In th trial 100% of patients achieved the primary endpoint of skin toxicity improvement by week 6 and 66% of patients reported a reduction in skin pain and itching.
These results highlight HT-001's potential to set a new standard of care for cancer patients, offering a safe and effective solution to maintain cancer treatments while managing cutaneous side effects.
“These results are a significant milestone, underscoring HT-001's potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments,” said Robb Knie, CEO of Hoth Therapeutics. “Our data highlight HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area.”
Exceptional Patient Outcomes:
Data from the open-label portion of the CLEER-001 trial demonstrated remarkable success:
- 100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.
- 66% of patients reported reduced pain and itching scores, further enhancing quality of life.
Crucially, all patients maintained their full EGFRi dosage , preserving the cancer treatment's full therapeutic effect-a notable improvement compared to past reports showing widespread dose reductions or treatment halts due to skin-related side effects.
A Groundbreaking Approach:
The trial uses the proprietary Acneiform Rash Investigator Global Assessment Scale (ARIGA), developed in collaboration with onco-dermatology experts. The innovative scale ensures precise measurement and assessment of skin toxicity improvements.
Robb Knie , CEO of Hoth Therapeutics, remarked, "These results are a significant milestone, underscoring HT-001's potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments. Our data highlight HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area."
A Strong Safety Profile:
No treatment-related adverse effects have been reported, reaffirming HT-001's excellent tolerability.
Looking Ahead:
"These interim findings align with a recent case report of rapid resolution of EGFRi-induced skin conditions using HT-001," added Knie. "As the study progresses, we anticipate further validating these results and are excited about the potential impact HT-001 could have on patient outcomes."
Hoth Therapeutics is committed to advancing groundbreaking treatments and improving patient lives through innovative therapies like HT-001.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751